The 2024 semaglutide phase 2 RCT and the Weill Cornell cohort data are the most rigorous current evidence showing bone loss - but reasonable endocrinologists interpret even those findings with appropriate uncertainty about generalizability
The clinical trial data from both Phase 2 (Jastreboff et al., NEJM 2023) and Phase 3 (TRIUMPH-4, Eli Lilly press release December 2025) provide a detailed picture of the weight loss trajectory over time
For researchers who are not reaching their target blood sugar or HbA1c goals on tirzepatide alone, berberine provides a second mechanistic pathway
GLOBAL GLUTATHIONE MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION) TABLE 40
A fresh Pfizer GLP-1 deal this week proves they're all-in on diversification
Under NICE TA875, it is recommended for adults with a BMI of 35 kg/m and at least one weight-related comorbidity (or BMI 3034.9 kg/m in defined circumstances), when used as part of a specialist weight management service Liraglutide 3 mg (Saxenda) holds a UK marketing authorisation for weight management